This Article Full Text Full Text (PDF) Other Versions of this Article: JCM.02216-07v1 46/6/2095    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Mazzariol, A. Articles by Fontana, R. PubMed PubMed Citation Articles by Mazzariol, A. Articles by Fontana, R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2008, p. 2095-2098, Vol. 46, No. 6
0095-1137/08/$08.00+0     doi:10.1128/JCM.02216-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Performance of Vitek 2 in Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Isolates with Different Mechanisms of β-Lactam Resistance

Dipartimento di Patologia, Sezione di Microbiologia, Università di Verona,¹ Servizio di Microbiologia, Immunologia e Virologia, Azienda Ospedaliera, Verona, Italy²

Received 16 November 2007/ Returned for modification 18 January 2008/ Accepted 11 April 2008

A total of 78 isolates of Pseudomonas aeruginosa grouped according to the phenotype for ceftazidime and imipenem susceptibility/resistance were used to assess the accuracy of the Vitek 2 system in antimicrobial susceptibility testing. Comparisons were made with a MIC gradient test for piperacillin-tazobactam, ceftazidime, aztreonam, imipenem, meropenem, gentamicin, and ciprofloxacin. For the total of 546 isolate-antimicrobial combinations tested, the category agreement was 83.6%, with 2.0, 1.6, and 12.8% very major, major, and minor errors, respectively. Vitek 2 accuracy was influenced differently by the mechanism responsible for resistance, and interpretation of the results in relation to phenotype could improve the performance of the system.

Published ahead of print on 23 April 2008.